Biopharma Daily Stock Updates - 01/15/21

$XBI $151.73 (-1.11%) 📉

PIPELINE:

$AVEO (-0.37%) - AVEO Oncology Announces Results from Phase 1b Portion of DEDUCTIVE Study of Tivozanib (FOTIVDA®) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma

http://investor.aveooncology.com/news-releases/news-release-details/aveo-oncology-announces-results-phase-1b-portion-deductive-study

$FPRX (-10.90%) - Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemotherapy as a Frontline Targeted Treatment for FGFR2b+ Gastric and GEJ Cancers

https://investor.fiveprime.com/news-releases/news-release-details/phase-2-fight-trial-results-presented-asco-gi-validate

$PBYI (-2.00%) - Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI

https://investor.pumabiotechnology.com/news-releases/news-details/2021/Puma-Biotechnology-Presents-Interim-Results-from-the-Biliary-Tract-Cancers-Cohort-of-the-Phase-II-SUMMIT-Basket-Trial-of-Neratinib-at-ASCO-GI/default.aspx

$VBIV (+0.16%) - VBI Vaccines Announces Publication of Results from a Phase 4 Study of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine in Vaccine

https://www.vbivaccines.com/wire/results-of-phase-4-hepatitis-b-study/

$CRDF (-31.22%) - Cardiff Oncology Presents Data that Continues to Demonstrate the Clinical Benefit of Onvansertib in KRAS-Mutated mCRC and Initial Findings from its Expanded Access Program

https://cardiffoncology.investorroom.com/2021-01-15-Cardiff-Oncology-Presents-Data-that-Continues-to-Demonstrate-the-Clinical-Benefit-of-Onvansertib-in-KRAS-Mutated-mCRC-and-Initial-Findings-from-its-Expanded-Access-Program

$ZYME (-1.35%) - Zanidatamab Data Highlight Durable Antitumor Activity in HER2‑Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium

https://ir.zymeworks.com/News-Releases/news-details/2021/Zanidatamab-Data-Highlight-Durable-Antitumor-Activity-in-HER2Expressing-Biliary-Tract-and-Gastroesophageal-Cancers-at-ASCO-Gastrointestinal-Cancers-Symposium/default.aspx